Effective coronavirus reduction by various production steps during the manufacture of plasma‐derived medicinal products

摘要

Manufacturing processes of all plasma‐derived medicinal products (PDMPs) include dedicated virus removal or virus inactivation steps to provide a high safety margin against known or emerging viruses. The recent outbreak of the novel coronavirus SARS‐CoV‐2 in China and the subsequent pandemic prompted us to evaluate the safety of selected manufacturing steps of PDMPs focusing specifically on process steps where there is still a lack of published data with regard to coronavirus inactivation.